A comparative study of budigefu and budesonide formoterol inhalant in the treatment of chronic obstructive pulmonary disease in elderly patients
Objective To explore the therapeutic effects of budigefu and budesonide formoterol inhalant on elderly pa-tients with moderate to severe chronic obstructive pulmonary disease(COPD)and their impact on serum inflammatory factors level.Methods The clinical data of elderly patients with moderate to severe COPD admitted to People's Hospital of Luzhou City from January 2023 to May 2023 were retrospectively analyzed.All patients were treated with a stable COPD treatment plan.Patients treated with budigefu inhalation aerosol were assigned to budigefu group and patients treated with budesonide for-moterol powder inhalant were assigned to budesonide formoterol group according to different therapeutic drugs.Gender and age confounding factors were excluded by propensity score matching.48 cases were included in each group,and both groups re-ceived continuous treatment for 3 months.The clinical effect of both groups was observed.The pulmonary ventilation function indexes[forced expiratory volume(FEV,),forced vital capacity(FVC)and FEV1/FVC],exercise endurance(6MWD),COPD assessment test(CAT),Borg dyspnea score,blood gas indexes[arterial oxygen saturation(SaO2),arterial partial pressure of carbon dioxide(PaCO2),arterial partial oxygen pressure(PaO2)]and peripheral inflammatory markers[white blood cell count(WBC),C-reactive protein(CRP),serum amyloid A(SAA)and eosinophil absolute value(EOS)]before and after treatment were compared between the two groups.The adverse reactions during treatment were compared between the two groups.Results After treatment,the total effective rate of treatment in the budigefu group was higher than that in the budesonide formoterol group(95.83％vs 83.33％)(P＜0.05).After treatment,the levels of FEV,,FCV and FEV1/FVC in both groups increased(P＜0.05),6MWD increased(P＜0.05),CAT score and Borg score decreased(P＜0.05),PaO2 and SaO2 values increased(P＜0.05),PaCO2 values decreased(P＜0.05),the levels of WBC,CRP,SAA and EOS decreased(P＜0.05).But the above changes in the Budigefu group were larger than those in the budesonide formoterol group(P＜0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Compared with budesonide formoterol inhalants,budigefu aerosol inhalant showed more significant effects in eld-erly patients with moderate and severe COPD.It can significantly improve pulmonary ventilation function,enhance exercise en-durance and reduce inflammatory response,and has certain clinical application value.
国家科技期刊平台
NSTL
万方数据
